2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of thePolymyalgia Rheumatica Market?

The proliferation of personalized medicine, tailored to the genetic profile, lifestyle, and specific health conditions of an individual, is anticipated to boost the polymyalgia rheumatica market’s growth. Advances in genetic research, high patient expectations for specific treatments, and enhancements in diagnostic technologies are fueling the demand for personalized medicine. Genetic research has offered more in-depth insights into personal genetic variations, making way for tailored treatments focused on specific genetic markers. By considering the patient’s characteristics, personalized medicine aids in choosing the most effective drugs, resulting in a safer and more successful treatment plan. For instance, the Personalised Medicine Coalition cited that the Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, a significant rise from six in 2022. Consequently, the surge in personalized medicine is spurring the growth of the polymyalgia rheumatica market. In parallel, the expansion in telemedicine services is projected to stimulate the polymyalgia rheumatica market’s growth. Telemedicine services leverage digital communication means such as video calls, phone calls, and online messaging, providing remote consultations, diagnoses, treatments, and subsequent care to patients, eliminating the need for physical visits. The demand for telemedicine services, offering convenient and cost-effective healthcare solutions, is on the rise. It caters to the growing patient demand for easy healthcare options, particularly for non-emergent consultations, thereby bypassing the need for face-to-face visits. In terms of polymyalgia rheumatica, the expansion of telemedicine services facilitates remote symptom monitoring, medication management, and regular follow-ups, all vital for managing chronic pain and inflammation. The Australian Bureau of Statistics reported in November 2024 that the usage rate of telehealth consultations increased from 87.7% in 2022-23 to 89.2% in 2023-24. Therefore, the growth of telemedicine services is fuelling the expansion of the polymyalgia rheumatica market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp

#What is the Anticipated CAGR of thePolymyalgia Rheumatica Market, and What Factors Will Drive It?

The market size for polymyalgia rheumatica has experienced significant growth lately. It is projected to expand from $1.28 billion in 2024 to $1.36 billion in 2025, correlating to a compound annual growth rate (CAGR) of 6.6%. The growth during the prior period can be ascribed to increased comprehension among healthcare professionals, a surge in corticosteroids usage, expansion of specialty clinics, the unveiling of biologic treatments, and escalating healthcare budgets.

Strong development is anticipated in the polymyalgia rheumatica market in the upcoming years, predicted to expand to $1.73 billion by 2029, with a CAGR of 6.2%. The expansion during the forecast span can be credited to increasing use of biologics, proliferation of precision medicine, quickened drug approvals, comprehensive reimbursements, and the broadening of clinical trials. Considerable trends for the forecast era encompass the evolution of combination therapies, progress in personalized treatment, refinement of precision medicine, the assimilation of electronic health records, and breakthroughs in biomarkers.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22103

Which Upcoming Market Trends and Innovations Are Set to Influence thePolymyalgia Rheumatica Market’s Path Forward?

Prominent businesses in the polymyalgia rheumatica market are moving towards the creation of advanced medicinal drugs like interleukin-6 (IL-6) receptor blockers. These blockers are biological treatments that target and inhibit IL-6, an instrumental pro-inflammatory cytokine in autoimmune diseases. These treatments aim to reduce inflammation and enhance symptoms, thus improving the life quality of PMR patients. In February 2023, Regeneron Pharmaceuticals, Inc., from the USA, together with the French healthcare company Sanofi, shared news of the FDA approval for their drug Kevzara (sarilumab) to treat polymyalgia rheumatica in adults who did not benefit well enough from corticosteroids or struggled to wean off them. Kevzara, being the first biologic approved for this particular condition, functions by hindering IL-6 driven signaling. The approval was supported by a study that showed 28.3% of patients on sarilumab experienced sustained remission at week 52, as opposed to 10.3% on a placebo. The drug is taken bi-weekly through a subcutaneous injection and is also approved for treatment of moderately to severely active rheumatoid arthritis. Sanofi’s stock (SNY) on the NASDAQ is currently valued at $54.13.

Who Are the Dominant Market Players Pushing the Boundaries of thePolymyalgia Rheumatica Market?

Major companies operating in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Mount Sinai, NYU Langone Health, Mayo Foundation for Medical Education and Research, Hartford HealthCare, Horizon Therapeutics plc, Massachusetts General Hospital, Brigham and Women’s Hospital, Stanford Health Care, University Hospitals Bristol NHS Foundation Trust, Circle Health Group Ltd., Siloam Hospital, UC San Diego Health, Vejthani Hospital, Sparrow Pharmaceuticals Inc., Johns Hopkins Arthritis Center, Upstate University Hospital

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report

What Are the Core Segments of the Polymyalgia Rheumatica Market, and How Do They Contribute to Growth?

The polymyalgia rheumatica market covered in this report is segmented –

1) By Treatment: Corticosteroids, Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Biologics

2) By Route Of Administration: Oral, Intravenous, Subcutaneous

3) By Patient Type: Adult, Geriatric, Periatric

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Aspirin, Celecoxib

3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine

4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-6 (IL-6) Inhibitors, B-Cell Inhibitors, Janus Kinase (JAK) Inhibitors

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=22103&type=smp

What Regions Are Dominating the Polymyalgia Rheumatica Market Growth?

Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Polymyalgia Rheumatica Market 2025, By The Business Research Company:

Bipolar Disorder Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report

HPV Associated Disorders Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hpv-associated-disorders-global-market-report

Bleeding Disorders Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: